GlobalRPh Renal Dosing Masterv6.6
GlobalRPh source record

Pregabalin - immediate release

Local official-label summaryBase record retrieved 2026-09-05See the evidence for this drug3 sources available - open source summaries, references and comparisons
READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Cautions / source differences (1)
Review first - source-specific qualification

Daily total and overlapping source boundaries

Both selected tables express total mg/day and print overlapping endpoints at 30 and 60 mL/min. A daily amount is not a per-dose amount.

Before applying: Use the indication-specific column, divide as directed, and clarify exact boundary values rather than silently normalizing them.

Evidence for this qualification

Source-specific interpretation; independent clinician adjudication pending.

Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.

Choose a source to read (3)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

Official source

LYRICA - official adult renal table

Product / population
Immediate-release LYRICA capsules/oral solution; adult renal Table 2.
Renal measure
Cockcroft-Gault CrCl (mL/min)
Before using this finding

Use the indication-specific column and daily total. Printed endpoint overlaps are not silently normalized.

Renal guidance and important limits

Select the indication-specific normal-renal daily total, then the matching column below; the amounts are total mg/day, not mg/dose.

CrCl mL/minColumn 1Column 2Column 3Column 4Daily frequency
At least 601503004506002 or 3 divided doses
30-60751502253002 or 3 divided doses
15-3025-5075100-1501501 or 2 doses
Below 152525-5050-7575Once daily

Printed overlapping endpoints are retained; exact 30/60 need reconciliation. After each 4-hour HD session, supplement daily dosing: 25 mg/day regimen, add 25-50 mg; 25-50, add 50-75; 50-75, add 75-100; 75, add 100-150. Pediatric renal impairment was not studied. Consider dose-dependent adverse effects; this is not LYRICA CR.

Source revision: 4/2025 | Retrieved: 2026-09-10. Retrieval date is not the revision date.

Source: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=d4734e7d-5079-455e-8ff5-8f4539c998a9

Scope: Selected source sections stored locally. Not a complete monograph or independent clinical approval. GlobalRPh v6.6.

Full source card / provenance

All sources, comparison tools and evidence navigation
Source-specific interpretation

What the dialysis evidence actually supports

Removal information alone does not define a maintenance dose, supplemental dose or dialysis schedule. A reported regimen still requires its product, indication, renal measure and dialysis assumptions to match the patient.

LYRICA - official adult renal table

Authored v6.1; retrieved 2026-09-10 - retained source, not freshly reviewed in this release

A regimen is reported in selected content

Read the source and its limits

GlobalRPh RX List - LYRICA

Authored v6.1; retrieved 2026-09-10 - retained source, not freshly reviewed in this release

A regimen is reported in selected content

Read the source and its limits

These manual classifications apply only to the identified selected sections, not every retained source or the entire prescribing information. They are not dosing clearance.

Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Read 1 source difference / applicability notes

Preserved GlobalRPh source

Preserved original GlobalRPh source

Preserved historical content; not revalidated as current prescribing guidance.

Renal method: Read the measure and population stated in the original source sections.
Retrieved: 2026-09-05

Read local renal resultOpen original reference
Official product label

LYRICA - official adult renal table

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.
Before using this finding

Use the indication-specific column and daily total. Printed endpoint overlaps are not silently normalized.

Dialysis evidence: A regimen is reported in selected content

Immediate-release LYRICA capsules/oral solution; adult renal Table 2.

Renal method: Cockcroft-Gault CrCl (mL/min)
Retrieved: 2026-09-10

Read local renal resultOpen original reference
GlobalRPh RX List

GlobalRPh RX List - LYRICA

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.
Before using this finding

Daily total, indication and formulation must be selected before the renal row. Review exact boundary values with the source.

Dialysis evidence: A regimen is reported in selected content

LYRICA immediate-release capsules and oral solution; adult renal adjustment.

Renal method: Cockcroft-Gault CrCl (mL/min)
Retrieved: 2026-09-10

Read local renal resultOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Product / population check

Confirm the exact formulation before using a renal source

These links compare product identities, not interchangeable doses. A selected summary is not a complete prescribing monograph.

Source-quality holds
Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. Searches stay on this page and are not saved or sent.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources
Jump to renal guidanceRead 1 difference / caution notesClinician guide

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Read before choosing a regimen

Source differences and product cautions

Search differences across all drugs

These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.

source scope and renal guidance

Daily total and overlapping source boundaries

Both selected tables express total mg/day and print overlapping endpoints at 30 and 60 mL/min. A daily amount is not a per-dose amount.

How to use this: Use the indication-specific column, divide as directed, and clarify exact boundary values rather than silently normalizing them.

GlobalRPh RX List - LYRICALYRICA - official adult renal tablePregabalin - LYRICA CR extended release

Source-specific interpretation; independent clinician adjudication pending.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

New source summary - independent clinical review pending. Summaries of the identified label sections are included locally. Source import and numeric transcription checks are not independent two-reference validation. Do not treat this card as an approved institutional dosing protocol.

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scopeLYRICA - official adult renal tableGlobalRPh RX List - LYRICA
Choose two source checkboxes below.
Historical source content is not a current prescription. Original GlobalRPh recommendations are preserved, not automatically certified as current. Product-label and professional additions below are separately attributed. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.

Important source distinctions

Immediate-release source. This page does not provide an extended-release renal regimen. The source dialysis summary is reproduced as listed and is not expanded with unlisted rows.

Locally stored source content

Original GlobalRPh protocol

Clinical facts and comments transcribed into a structured reading format. This is not a byte-for-byte HTML archive. Original source: https://globalrph.com/renal/pregabalin/

Usual Dosing (Adults)

Diabetic peripheral neuropathy: start 50 mg orally three times daily; increase to 100 mg three times daily within 1 week depending on benefit/tolerability.

Postherpetic neuralgia: start 75 mg twice daily or 50 mg three times daily; may increase to 300 mg/day within 1 week. Usual maintenance 75-150 mg twice daily or 50-100 mg three times daily (150-300 mg/day). After 2-4 weeks at 300 mg/day with insufficient relief but good tolerability, may increase to 300 mg twice daily or 200 mg three times daily.

GRPH-pregabalin-01 · Source section: Usual Dosing (Adults)Renal section finder

Renal Dosing

CrCl above 60 mL/min: no change. 30-60: 75-300 mg/day in 2-3 doses. 15-30: 25-150 mg/day once daily or in two doses. Below 15: 25-75 mg once daily. The indication-specific normal regimen must be established before selecting within a renal range.

GRPH-pregabalin-02 · Source section: Renal DosingRenal section finder

Hemodialysis

Immediately after a 4-hour HD session, the source lists supplemental doses according to the daily regimen:

  • 25 mg daily: supplement 25 or 50 mg.
  • 25-50 mg daily: supplement 50 or 75 mg.
  • 75 mg daily: supplement 100 or 150 mg.
GRPH-pregabalin-03 · Source section: HemodialysisRenal section finder
Separate U.S. product-label layer

FDA / DailyMed dosing and renal information

Official

LYRICA - official adult renal table

Open original reference

Open / share this exact local source

National Library of Medicine / manufacturer labeling · Immediate-release LYRICA capsules/oral solution; adult renal Table 2.

Renal method: Cockcroft-Gault CrCl (mL/min)
Source date: 4/2025
Retrieved: 2026-09-10

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.
Before using this finding

Use the indication-specific column and daily total. Printed endpoint overlaps are not silently normalized.

Dialysis evidence: A regimen is reported in selected content

Selected source sections stored locally. Not a complete monograph or independent clinical approval.

Renal guidance and important limits

Select the indication-specific normal-renal daily total, then the matching column below; the amounts are total mg/day, not mg/dose.

CrCl mL/minColumn 1Column 2Column 3Column 4Daily frequency
At least 601503004506002 or 3 divided doses
30-60751502253002 or 3 divided doses
15-3025-5075100-1501501 or 2 doses
Below 152525-5050-7575Once daily

Printed overlapping endpoints are retained; exact 30/60 need reconciliation. After each 4-hour HD session, supplement daily dosing: 25 mg/day regimen, add 25-50 mg; 25-50, add 50-75; 50-75, add 75-100; 75, add 100-150. Pediatric renal impairment was not studied. Consider dose-dependent adverse effects; this is not LYRICA CR.

RDM61-official-pregabalin-2b7ae43e92-C1 · Source locator: 2.7 and Table 2

Source identity and provenance
Source family
product_label
Source
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=d4734e7d-5079-455e-8ff5-8f4539c998a9
Retrieved
2026-09-10
Exact label title
LYRICA - official adult renal table
DailyMed Set ID
d4734e7d-5079-455e-8ff5-8f4539c998a9
Labeler
Viatris Specialty LLC
Label revision
4/2025
SPL version
18
Renal-function method
Cockcroft-Gault CrCl (mL/min)
Source date/version
4/2025
Hash meaning
Local authored summary, not source HTML/XML/PDF bytes
Local summary SHA-256
85743dcdc3756345b7885748eb4458a02e6991ab24ee134bf9069d66f37e052f
Locally imported selected renal sections

GlobalRPh RX List renal information

Rxlist

GlobalRPh RX List - LYRICA

Open original reference

Open / share this exact local source

GlobalRPh-hosted RX List · LYRICA immediate-release capsules and oral solution; adult renal adjustment.

Renal method: Cockcroft-Gault CrCl (mL/min)
Source date: Revision not established in selected retrieval
Retrieved: 2026-09-10

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.
Before using this finding

Daily total, indication and formulation must be selected before the renal row. Review exact boundary values with the source.

Dialysis evidence: A regimen is reported in selected content

Selected source sections stored locally. Not a complete monograph or independent clinical approval.

Renal guidance and important limits

LYRICA uses Cockcroft-Gault creatinine clearance and the indication-specific normal-renal total daily dose to select the corresponding renal-adjusted daily amount. Divide that total into the stated number of administrations; it is not milligrams per administration. A supplemental dose follows every 4-hour hemodialysis session in addition to renal-adjusted daily dosing. The printed categories overlap at 30 and 60 mL/min; do not conceal this source-table boundary issue. This immediate-release table is not a LYRICA CR conversion.

RDM61-rxlist-pregabalin-f1767cfe33-C1 · Source locator: Dosage and Administration: renal impairment; named precautions

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/lyrica-drug/
Retrieved
2026-09-10
Renal-function method
Cockcroft-Gault CrCl (mL/min)
Source date/version
Revision not established in selected retrieval
Hash meaning
Local authored summary, not source HTML/XML/PDF bytes
Local summary SHA-256
7dc3fe350e61d802dedfde6e6e4d1ac3cc83015b6e84df939a795cdbb05f639d

Provenance and preservation

Additional summaries stored on this page: 1 official-label, 1 RX List, 0 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://globalrph.com/renal/pregabalin/
Source retrieval
2026-09-05. This is not the source publication or label revision date.
Original source type
globalrph individual
Local text SHA-256
a26e687be41b3683708dbdc26ec4104f4877af53ac54be4ade1dfea14e86688d
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

The original individual GlobalRPh pages commonly cite NIH/NLM DailyMed and instruct readers to review the applicable package insert for updates. That historical reference is preserved as context; it is not counted as an independently retrieved current label.

Read the full coverage report